Study design
HCC
A randomized, placebo-controlled, double-blind, multicenter clinical trial was performed on FOLFOX4-ATRA versus FOLFOX4-placebo in advanced HCC patients with EHM. Written informed consent of each participant was obtained. Randomization was performed by an independent statistician using SAS 9.4 SID to generate randomization. Eligible subjects who were enrolled in the study received a unique subject identification number, and they were randomly assigned to the FOLFOX4-ATRA or FOLFOX4-placebo treatment group at a ratio of 1:1. ATRA tablets and placebos had the same appearance, packaging, and administration schedules. Both the subjects and investigators were blinded to the treatments until emergency unblinding or after database lock.This trial was registered on Chinese Clinical Trail Registry (ID: ChiCTR-IIR-17012916, 